NC
NBIX icon

nVerses Capital’s Neurocrine Biosciences NBIX Stock Holding History

nVerses Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
+1,259
New +$187K 0.33% 176
2024
Q4 		– Sell
-3,400
Closed -$392K – 560
2024
Q3 		$392K Buy
+3,400
New +$466K 0.18% 177

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

nVerses Capital's NBIX Position: Q2 2026 in Review

nVerses Capital opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,259 shares worth $212K. The stake represents 0.33% of the portfolio and ranks #176 among its holdings. This is a return to the name: nVerses Capital previously reported a position in NBIX as recently as Q3 2024.

nVerses Capital first reported a position in NBIX in Q3 2024 and has held it in 2 quarters since. The position peaked at $392K in Q3 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • nVerses Capital held 1,259 shares of Neurocrine Biosciences worth $212K as of Q2 2026.
  • Neurocrine Biosciences was a new nVerses Capital position in Q2 2026.
  • Neurocrine Biosciences made up 0.33% of nVerses Capital's portfolio in Q2 2026, its #176 holding.
  • nVerses Capital first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 2 quarters since.
  • nVerses Capital's Neurocrine Biosciences position peaked at $392K in Q3 2024.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.